CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 37 enrolled
Drug / intervention
Ciclesonide +1 moredrug
Likely dose
Ciclesonide 160 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00306163
NCT00306163Phase 3Completed
CompareCT.gov

Nebulizer Trial: Evaluation of the Influence of Particle Size of Aerosolized AMP on Bronchial Responsiveness in Patients With Asthma and the Effects of Treatment With Ciclesonide Versus Fluticasone.

AstraZeneca·interventional·Posted Mar 23, 2006·Updated Feb 1, 2017

In Brief

A Phase 3 clinical trial evaluating Ciclesonide and Fluticasone for Asthma. Completed, enrolled 37 participants across 1 site.

Detailed Summary

The aim of this study is to compare the responsiveness of lower airways in adult patients with stable asthma after treatment with ciclesonide and fluticasone propionate. Treatment medication will be administered as follows: ciclesonide will be inhaled once daily at one dose level, fluticasone propionate will be inhaled twice daily at one dose level. The study duration consists of a baseline period (5 weeks) and a treatment period (5 weeks). The study will provide further data on safety and tolerability of ciclesonide.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesNetherlands
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 23, 2006
Enrollment StartMay 1, 2006
Primary CompletionAug 1, 2008
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.3 years ago

Interventions

Ciclesonidedrug

inhaled Ciclesonide 160 µg, once daily in the morning

Fluticasonedrug

inhaled Fluticasone 100 µg, twice daily